This is a phase 3, multicenter, open-label study to evaluate the safety of QM1114-DP for the long term treatment of moderate to severe Glabellar (Frown) Lines (GL) and Lateral Canthal Lines (Crow's Feet and LCL).
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
902
A dose of QM1114-DP will be injected in the GL area and in the LCL area.
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown
4-point scale
Time frame: Week 4
Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the LCL Investigator Scales at Maximum Smile
4-point scale
Time frame: Week 4
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, United States
Investigate MD, LLC.
Scottsdale, Arizona, United States
Center for Dermatology Clinical Research, Inc.
Fremont, California, United States
Rejuva Medical Aesthetics, LLC
Los Angeles, California, United States
Westside Aesthetics
Los Angeles, California, United States
Marcus Facial Plastic Surgery
Redondo Beach, California, United States
The Maas Clinic Research Center
San Francisco, California, United States
ArteMedica
Santa Rosa, California, United States
AboutSkin Research, LLC
Greenwood Village, Colorado, United States
Modern Dermatology PC
Westport, Connecticut, United States
...and 20 more locations